Clinical trials
Observational Macular Degeneration trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insel Gruppe AG, University Hospital Bern | 5 |
| Medical University of Vienna | 2 |
| Association for Innovation and Biomedical Research on Light and Image | 1 |
| Boehringer Ingelheim | 1 |
| Dr. med. Katja Hatz | 1 |
| Institute of Molecular and Clinical Ophthalmology Basel | 1 |
| Kubota Vision Inc. | 1 |
| Novartis Pharmaceuticals | 1 |
| University Hospital, Basel, Switzerland | 1 |
| University of Southampton | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Degeneration | 16 |
| Retinal Vein Occlusion | 3 |
| Geographic Atrophy | 2 |
| Macular Edema | 2 |
| Atrophy | 1 |
| Choroidal Neovascularization | 1 |
| Diabetic Retinopathy | 1 |
| Glaucoma | 1 |
| Hypertensive Retinopathy | 1 |
| Optic Nerve Diseases | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.